Biofil Chemicals and Pharmaceuticals Limited

Total Valuation

Biofil Chemicals and Pharmaceuticals Limited carries a market capitalization of 557.21M, placing it among publicly traded companies globally. Its enterprise value stands at 546.64M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Valuation Ratios

Biofil Chemicals and Pharmaceuticals Limited trades at a trailing price-to-earnings ratio of 19.71.

Enterprise Valuation

On an enterprise value basis, Biofil Chemicals and Pharmaceuticals Limited trades at an EV/EBITDA multiple of 1,307.75 and an EV/FCF ratio of 3,664.00. The EV/Sales ratio of 1.87 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 1,307.75 provides insight into valuation relative to core operating earnings.

Financial Position

Biofil Chemicals and Pharmaceuticals Limited maintains a current ratio of 2.77, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.60, indicating elevated leverage, while an interest coverage ratio of 2.40 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Biofil Chemicals and Pharmaceuticals Limited has paid 4.61M in income taxes, reflecting an effective tax rate of 14.26.

Stock Price Statistics

Biofil Chemicals and Pharmaceuticals Limited's stock has declined approximately -29.51832% over the past 52 weeks. The 50-day moving average sits at 32.37, while the 200-day moving average is 35.77.

Income Statement

Over the trailing twelve months, Biofil Chemicals and Pharmaceuticals Limited generated 291.81M in revenue and converted that into 27.74M in net income, yielding earnings per share of 1.70. EBITDA reached 418,000.00, while operating income came in at 418,000.00.

Margins

Biofil Chemicals and Pharmaceuticals Limited operates with a gross margin of 7.73, reflecting its pricing power and cost economics. The operating margin of 0.14 and net profit margin of 9.50 provide insight into operational efficiency.

Scores

Biofil Chemicals and Pharmaceuticals Limited posts an Altman Z-Score of 3.26, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.